News & Updates

Show Multimedia Only
Delgocitinib ointment safely reduces symptoms in paediatric atopic dermatitis

Delgocitinib ointment safely reduces symptoms in paediatric atopic dermatitis

31 Oct 2025 byStephen Padilla

Treatment with delgocitinib ointment, a topical Janus kinase (JAK) inhibitor, for paediatric atopic dermatitis (AD) is effective and well tolerated when applied for up to 56 weeks, according to a phase III trial and a subsequent open-label, long-term study in Japan.

Delgocitinib ointment safely reduces symptoms in paediatric atopic dermatitis

31 Oct 2025
Maternal TDF, infant HBV vax, HBIg-free strategy prevent infant hep B

Maternal TDF, infant HBV vax, HBIg-free strategy prevent infant hep B

01 Apr 2025 byAudrey Abella

In the absence of infant hepatitis B immune globulin (HBIg), maternal tenofovir disoproxil fumarate (TDF) prophylaxis combined with infant hepatitis B virus (HBV) immunization provide sufficient protection against HBV infection in infants, findings from the iTAP-2 study suggest. However, the risk of infection was not demonstrably below 2 percent.

Maternal TDF, infant HBV vax, HBIg-free strategy prevent infant hep B

01 Apr 2025